226 related articles for article (PubMed ID: 12722392)
21. Is a low dose of dexamethasone sufficient to prevent paclitaxel-related hypersensitivity reactions? A retrospective study in patients with gynecologic malignancy.
Xiao D; Yang Z; Shi Y; Yang W; Zhang Y
Expert Rev Clin Pharmacol; 2024; 17(5-6):525-532. PubMed ID: 38652518
[TBL] [Abstract][Full Text] [Related]
22. Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions.
Yamada Y; Shirao K; Ohtsu A; Boku N; Hyodo I; Saitoh H; Miyata Y; Taguchi T
Ann Oncol; 2001 Aug; 12(8):1133-7. PubMed ID: 11583196
[TBL] [Abstract][Full Text] [Related]
23. Hypersensitivity reactions in ovarian cancer patients receiving paclitaxel.
Cormio G; Di Vagno G; Melilli GA; Cazzolla A; Di Gesù G; Carriero C; Cramarossa D; Loverro G; Selvaggi L
J Chemother; 1999 Oct; 11(5):407-9. PubMed ID: 10632389
[TBL] [Abstract][Full Text] [Related]
24. Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments.
Feldweg AM; Lee CW; Matulonis UA; Castells M
Gynecol Oncol; 2005 Mar; 96(3):824-9. PubMed ID: 15721432
[TBL] [Abstract][Full Text] [Related]
25. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum.
Rosenberg P; Andersson H; Boman K; Ridderheim M; Sorbe B; Puistola U; Parö G
Acta Oncol; 2002; 41(5):418-24. PubMed ID: 12442916
[TBL] [Abstract][Full Text] [Related]
26. Paclitaxel administered by 1-hour infusion. Preliminary results of a phase I/II trial comparing two schedules.
Hainsworth JD; Greco FA
Cancer; 1994 Aug; 74(4):1377-82. PubMed ID: 7914470
[TBL] [Abstract][Full Text] [Related]
27. Paclitaxel and simultaneous radiation in locally advanced stage IIIA/B non-small cell lung cancer: a clinical phase I study.
Vogt HG; Kolotas C; Martin T; Schneider LV; Goes-Schmieder R; Mitrou PS; Diergarten K; Kober B; Zamboglou N
Semin Oncol; 1996 Dec; 23(6 Suppl 16):120-3. PubMed ID: 9007138
[TBL] [Abstract][Full Text] [Related]
28. Retrospective evaluation of weekly paclitaxel hypersensitivity reactions reported utilizing an electronic medical record system at a tertiary cancer center.
Lal LS; Gerber DL; Lau J; Dana W
Support Care Cancer; 2009 Oct; 17(10):1311-5. PubMed ID: 19184123
[TBL] [Abstract][Full Text] [Related]
29. Intravenous versus oral dexamethasone for prophylaxis of paclitaxel-associated hypersensitivity reaction in patients with primary ovarian, fallopian tube and peritoneal cancer: A double-blind randomized controlled trial.
Yanaranop M; Chaithongwongwatthana S
Asia Pac J Clin Oncol; 2016 Sep; 12(3):289-99. PubMed ID: 27098551
[TBL] [Abstract][Full Text] [Related]
30. Cetirizine versus diphenhydramine in the prevention of chemotherapy-related hypersensitivity reactions.
Durham CG; Thotakura D; Sager L; Foster J; Herrington JD
J Oncol Pharm Pract; 2019 Sep; 25(6):1396-1401. PubMed ID: 30419768
[TBL] [Abstract][Full Text] [Related]
31. Impact of institutional interventions on the rate of paclitaxel hypersensitivity reactions.
Jao ME; Indorf AL; Segal EM; Miske A; Eaton KD; Marsolini T; Ghuman S
J Oncol Pharm Pract; 2024 Jan; 30(1):105-111. PubMed ID: 37021579
[TBL] [Abstract][Full Text] [Related]
32. Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center.
Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
J Clin Oncol; 2000 Jan; 18(1):102-5. PubMed ID: 10623699
[TBL] [Abstract][Full Text] [Related]
33. Do Steroids Matter? A Retrospective Review of Premedication for Taxane Chemotherapy and Hypersensitivity Reactions.
Lansinger OM; Biedermann S; He Z; Colevas AD
J Clin Oncol; 2021 Nov; 39(32):3583-3590. PubMed ID: 34357780
[TBL] [Abstract][Full Text] [Related]
34. Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy.
Sendo T; Sakai N; Itoh Y; Ikesue H; Kobayashi H; Hirakawa T; Nakano H; Oishi R
Cancer Chemother Pharmacol; 2005 Jul; 56(1):91-6. PubMed ID: 15791461
[TBL] [Abstract][Full Text] [Related]
35. [Weekly administration of paclitaxel for advanced or metastatic breast cancer--short-course premedications for outpatients].
Kimura M; Koida T; Yanagita Y
Gan To Kagaku Ryoho; 2000 Oct; 27(11):1703-8. PubMed ID: 11057321
[TBL] [Abstract][Full Text] [Related]
36. Meta-analysis of the effects of oral and intravenous dexamethasone premedication in the prevention of paclitaxel-induced allergic reactions.
Chen FC; Wang LH; Zheng XY; Zhang XM; Zhang J; Li LJ
Oncotarget; 2017 Mar; 8(12):19236-19243. PubMed ID: 27911278
[TBL] [Abstract][Full Text] [Related]
37. Successful re-treatment with taxol after major hypersensitivity reactions.
Peereboom DM; Donehower RC; Eisenhauer EA; McGuire WP; Onetto N; Hubbard JL; Piccart M; Gianni L; Rowinsky EK
J Clin Oncol; 1993 May; 11(5):885-90. PubMed ID: 8098057
[TBL] [Abstract][Full Text] [Related]
38. Taxol hypersensitivity: rapid retreatment is safe and cost effective.
Olson JK; Sood AK; Sorosky JI; Anderson B; Buller RE
Gynecol Oncol; 1998 Jan; 68(1):25-8. PubMed ID: 9454655
[TBL] [Abstract][Full Text] [Related]
39. Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing two previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy.
Parinyanitikul N; Tanpipattanakul W; Poovorawan N; Rattananupong T; Laoitthi P; Sithidetphaiboon P; Thanasanvimon S; Sriuranpong V
Support Care Cancer; 2018 Jul; 26(7):2471-2477. PubMed ID: 29435713
[TBL] [Abstract][Full Text] [Related]
40. Rapid intravenous premedication with dexamethasone prevents hypersensitivity reactions to paclitaxel.
Gennari A; Salvadori B; Tognoni A; Conte PF
Ann Oncol; 1996 Nov; 7(9):978-9. PubMed ID: 9006754
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]